Breast cancer treatments have been associated with an increased risk of multiple health-related adverse outcomes, but the relationship with diabetes remains unclear. This study investigated the association between hormone therapy and diabetes risk in breast cancer survivors.
INTRODUCTION
Breast cancer has become an increasingly survivable disease probably because of the continued improvements in detection interventions and advancements in treatment. 1 However, many survive only to be faced with another debilitating illness that is absent or subclinical at the end of therapy. 2 One such sequel is diabetes. Diabetes is a major contemporary health problem, with escalating prevalence projected to 552 million people affected globally by 2030. 3 Previous studies have suggested diabetes as an independent risk factor for the development of breast cancer, 4, 5 but few have investigated the inverse direction: breast cancer induction of diabetes. The risk of diabetes may be mediated by common shared risk factors such as old age, obesity, 6 insulin resistance, 7 sedentary lifestyle, and diet, 8 and emerging evidence, although limited by its infancy, points to breast cancer adjuvant treatment as potentially leading to the development of diabetes. [9] [10] [11] [12] [13] The precise biologic mechanism remains unclear. Weight gain 10 and hyperglycemia 11 have been proposed in the chemotherapy setting, whereas dysregulations in insulin secretion associated with estrogen depletion and subsequent alterations in glucose homeostasis 9, 12 have been suggested as plausible pathways in the hormone therapy (HT) setting. Estrogens modulate insulin resistance and may exert a direct protective effect against various injuries on the pancreatic b-cell islets that produce insulin. Both insulin resistance and pancreatic b-cell dysfunction are central disorders in the pathogenesis of diabetes.
14 Hormonal treatment with tamoxifen, a selective estrogen receptor Author affiliations and support information (if applicable) appear at the end of this article.
modulator, or aromatase inhibitors (AIs), which block estrogen production, can disrupt the estrogen-insulin interplay and elevate the risk of diabetes.
Notwithstanding improved survival, breast cancer is considered a leading cause of cancer morbidity and mortality among women worldwide. 15 The aggravated risk of diabetes, which can negatively affect breast cancer prognosis and substantially increase risk of all-cause mortality, [16] [17] [18] also worsens this picture. Given the detrimental impact of diabetes on breast cancer survival, additional exploration of the role of breast cancer treatment in the development of diabetes is important not only because it would add valuable information on the etiology of diabetes but also because it would help to identify high-risk patients in need of accentuated clinical care. To date, however, no clear consensus exists about which breast cancer treatment may induce diabetes. The effect of chemotherapy, if it exists, tends to be short term, 11 whereas the effect of HT is believed to extend longer. 12 We hypothesized a priori that HT is the principal modifier of a possible relation between breast cancer and diabetes and undertook this study to test this hypothesis.
PATIENTS AND METHODS

Study Design
We performed a case-cohort study nested within a longitudinal patient-based cohort study that estimated long-term treatment healthrelated adverse outcomes in breast cancer survivors. Consistent with the applied case-cohort design, covariate information was collected in all cases and in a representative sample of the parent cohort designated as the subcohort.
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Source cohort. On the basis of the National Health Insurance Law (1995), all Israeli citizens are insured by one of four health care funds at their discretion. Study patients were female members of Leumit Health Services (LHS), a nonprofit Israeli health care fund that covers approximately 10% of the total population. These patients were breast cancer survivors for at least 1 year and treated for early-stage or regionally advanced invasive breast cancer between January 1, 2002, and December 31, 2012. Localized and regional stages were selected to guarantee standardized treatment procedures and to avoid differential survival rates that may influence the development of diabetes. 9 Patients were considered ineligible if they had in situ or metastatic breast cancer, had a previous history of any type of cancer, or did not survive or were disenrolled from LHS during the first year after diagnosis. A total of 5,142 patients with a diagnosis of female breast cancer (International Classification of Diseases, Ninth Revision, code 174.x) were initially identified from LHS administrative databases. By linkage with the Israel National Cancer Registry (INCR) and a careful review of LHS electronic medical records for case ascertainment, 5,085 patients were confirmed to have a true diagnosis of breast cancer, of whom 2,644 matched the inclusion criteria. A 20% random sample (ie, the subcohort) was selected at baseline.
Diabetes parent cohort. The source cohort was further limited to breast cancer survivors with no history of diabetes before or during the first year after diagnosis. The rationale for the 1-year conditional diabetes-free survival was to ensure a sufficient period for commencement of HT. Three hundred ninety-eight women with prevalent diabetes (15%) were excluded. In total, 2,246 breast cancer survivors were included and observed until the occurrence of diabetes (index date), death, LHS disenrollment, or the predetermined censoring date (May 31, 2016) , whichever occurred first. Time at risk began 1 year after breast cancer diagnosis.
Subcohort and patients. Data processing was restricted to the randomly selected subcohort of 448 breast cancer survivors and all who developed diabetes during the study period (n = 324). A fraction of the diabetes incident cases was part of the subcohort (n = 57). Of the 715 eligible candidates for the administration of a constructed questionnaire, 145 were not contacted because they had died. The remaining 570 women, representatives of breast cancer survivors who were alive at the time of the study (n = 1,780), were contacted, and all completed the survey questionnaire (Fig 1) .
Data Collection
LHS pharmacy claims and the diagnoses billing database were used to obtain information on HT and diabetes, respectively. Information on potential confounders were elicited from LHS and INCR administrative databases along with a questionnaire. Validation of these databases and resolution of discrepancies among sources have been described in detail elsewhere.
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HT exposure. HT was received by 82% of the 570 cases and the subcohort within 6 months after breast cancer diagnosis for a median duration of 5 years (interquartile range, 4 to 6 years). HT was started before diagnosis of diabetes in all cases, with . 90% receiving treatment at least 1 year before the index date. However, the treatment was not completed in . 80% of cases by the time of the diabetes diagnosis. The mean lead time after the index date was 1.5 6 0.2 years. The treatment protocol was predominantly based on sequential therapy (70%) with the use of AIs after 2 to 3 years of tamoxifen to complete 5 years of HT; with the exception of five patients who began AIs (1%) but experienced intolerable adverse effects (as witnessed through review of their medical records) and switched to tamoxifen. Only 5% of those treated with HT received AIs alone. HT discontinuation was too low (median, 0.08; interquartile range, 0.00 to 0.16 years) to be considered in analyses.
Outcome measure. The primary outcome was diabetes-free survival, which was defined as the time from study entry (1 year after breast cancer diagnosis) to a first diagnosis of diabetes (International Classification of Diseases, Ninth Revision, code 250.x) in the LHS electronic encounter codes. The accuracy of the administrative code for diabetes was shown to be high through a previously validated algorithm that is based on laboratory measurements, procurement of diabetes medications, and review of medical records. 20 The positive and negative predictive values were 94.8% (95% CI, 75.4% to 99.1%) and 100% (95% CI, 96.3% to 100%), respectively. 20 Of note, diabetes has been used along with five other health care areas to assess the quality of community health care in Israel 21 ; thus, health care funds, including LHS, have invested efforts to diagnose the disease accurately.
Covariates. Information extracted from the INCR included breast cancer diagnosis date, age at diagnosis, immigration status, clinical stage at diagnosis, type of surgery, and axillary lymph node dissection. Supplementary information on region of residence, mean household income (derived from census data on the basis of patient residence), comorbid conditions at time of breast cancer diagnosis, receipt of adjuvant treatment, estrogen receptor status, lymph node involvement, health services utilization, and all-cause mortality were abstracted from LHS registries. The questionnaire, which was delivered in 2016 only to the subcohort and to breast cancer survivors diagnosed with diabetes, collected data on ethnicity, cohabitation status, education, parity, menopausal status at breast cancer diagnosis, family history of diabetes, work history, and lifestyle.
Ethics
The study protocol was reviewed and approved by the institutional review boards of LHS and the University of Haifa and in accordance with the Declaration of Helsinki, and all procedures complied with current Israeli laws. Patients were fully informed of the study objectives and procedures, and oral informed consent was obtained from each.
Statistical Analysis
Diabetes excess prevalence relative to the general population was quantified on the basis of data derived from the National Program for Quality Indicators in Community Healthcare in Israel for the period of 2010 to 2013. [22] [23] [24] We used cumulative incidence function to estimate the crude incidence of diabetes among the parent diabetes population in the presence of death as a competing risk. 25 To assess the independent relation between breast cancer HT and diabetes risk, multiple weighted Cox proportional hazards regression models were applied. Impact measures of attributable risk fraction and population attributable fraction (PAF) were assessed.
In a secondary analysis, we tested the effect of HT duration on risk of diabetes to address the potential of surveillance bias related to accentuated care and increased probability of outcome detection in patients who initiated treatment. 9 We dichotomized treatment duration using the 1-year cut point to preserve temporality.
Additional analysis by HT agent was performed. Because agent switch in the sequential setting could occur after the outcome, only the first received agent was considered. Details of the statistical methods used are provided in the Appendix (online only).
RESULTS
Diabetes prevalence rates in the source population of 2,644 breast cancer survivors increased drastically from 6% in 2002 to 28% in 2015 and was above the national norms in 2010 to 2013 (standardized prevalence ratios, 1.61 to 1.81; P , .001). After excluding patients with prevalent diabetes at baseline (n = 398) and after 13 years of observation (mean follow-up, 5.9 years), the crude cumulative incidence rate of diabetes in the presence of death as a competing risk was 20.9% (95% CI, 18.3% to 23.7%).
A total of 570 subcohort and diabetes cases alive at the time of the study were included in the analysis. The mean age at diagnosis was 55.5 years (SE, 0.5 years), and the mean time elapsed since diagnosis was 6.4 years (SE, 0.1 years). Overall, participants were jco.org predominantly non-Arab (93.9%) and married (68.9%). Detailed clinical and demographic characteristics of diabetes cases and noncases are listed in Table 1 . At baseline, diabetes cases were more likely to be older and less educated than subcohort noncases. Over the course of follow-up, diabetes cases made more frequent outpatient visits, consumed more diabetes-promoting drugs (except for steroids), and received HT for longer periods than noncases.
Lifestyle components collected after the index date indicated an unhealthy behavior associated with diabetes characterized by obesity, poor nutrition, and lack of physical activity. Diabetes cases, however, were more successful at controlling their weight than noncases (Table 2) .
In multivariable-adjusted models, HT use was associated with a significantly greater risk of diabetes than no HT use (hazard ratio [HR], 2.40; 95% CI, 1.26 to 4.55; P = .008; Table 3) . At the population level, the PAF, which is the proportion of diabetes incidence that could have been prevented among the entire diabetes cohort had patients not received HT, was 48%. Additional modeling of diabetes risk by HT agent revealed significant positive associations with tamoxifen and AIs ( Table 3 ). Notwithstanding that the strength of association and resultant attributable risk fraction were more pronounced with AIs, because of the low prevalence of AIs among patients with diabetes (6%), which in turn may explain the relatively wide CIs of the point estimate, the associated PAF was considerably lower than that of tamoxifen. When HT duration was considered, the risk of diabetes was significantly elevated during the entire course of HT (Table 3) . However, the number of patients in the HT duration interval # 1 year or in the AI subgroup was too small for a valid interpretation of the results.
In sensitivity analyses, the significance level of HT in relation to diabetes persisted in both the propensity score and the multiple imputation models, whereas the risk estimates were (Table 4) .
DISCUSSION
In this case-cohort study, we demonstrated a positive relationship between HT and diabetes. That HT effects remained significant after propensity score adjustment, which indicated that selection bias for HT was not a driving factor for the observed association, Abbreviations: ARF, attributable risk fraction; CF, case fraction (number of exposed cases divided by overall number of cases); HR, hazard ratio; IDR, incidence density rate (per 1,000 person-years); PAF, population attributable fraction; PY, person-years. *PY lived in the total cohort extrapolated from the random subcohort data; sampling weight, 1,780/356 = 5.00. †Adjusted for ethnicity; residence; cohabitation status; income; education; employment during treatment; chemotherapy type; hypertension; outpatient visits; use of corticosteroids, thiazide diuretics, b-blockers, and statins; and year of breast cancer diagnosis. Education, income, outpatient visits, and year of breast cancer diagnosis were modeled in all analyses as continuous variables to avoid the loss of information. Employment before breast cancer diagnosis, estrogen receptor status, and glucocorticoids were not introduced in all models to avoid multicollinearity.
together with the finding of persistent diabetes risk throughout the HT period despite intensified outpatient visits among cases build on and reinforce a previous conclusion by Lipscombe et al, 9 who argued against increased medical surveillance and precipitated diabetes detection around the time of breast cancer diagnosis and treatment. Nevertheless, because of the small sample size, the current study results should be replicated in a larger communitybased sample.
With respect to hormone agent, the findings substantiate previous suggestions of tamoxifen as a predominant mediator that links breast cancer to the induction of diabetes, 9, 12 although the measure of association in the current sample was to some extent stronger in magnitude. The discrepancy in estimates could be attributed to heterogeneity in HT prevalence, diabetes incidence, or sample size but also could be related to the extent to which confounding variables have been considered. We attempted to control for a relatively large constellation of demographic and clinical variables that were occasionally not available in corresponding studies, such as menopausal status and parity.
The increased risk associated with AIs observed in this study was inconsistent with other reports that found no effect 9 or even a protective effect 12 of these agents. However, one study acknowledged that the lack of association between AIs and diabetes could be related to the small proportion of AI users in that study (type II error), 9 whereas in the other, no plausible explanation for the inverse relation was provided, 12 which renders the validity of these findings questionable, particularly when a breast cancer survivorship care guideline 27 stated, in concordance with the current results, that AIs could raise the risk of diabetes.
Of note, the AI findings observed in this study support the underlying mechanism related to the effects of estrogen inhibition that these studies proposed. 9, 12 Estrogens play a potential role in the control of energy balance and glucose homeostasis.
14 Estrogen deficiency enhances metabolic dysfunction and predisposes to obesity and progression of the metabolic syndrome, wellestablished risk factors of diabetes.
14, 28 Estrogens also may ameliorate insulin resistance, which is a central disorder in the pathogenesis of diabetes.
14 Evidence documented in in vitro and in vivo models 29 and subsequently confirmed in humans 30 suggests that estrogens may regulate insulin secretion by exerting a direct protective effect on pancreatic islets, which augments b-cell hyperplasia and survival against multiple proapoptotic oxidative and lipotoxic stimuli.
14,31, 32 The antidiabetic actions of estrogens have been confirmed in randomized controlled trials. 33, 34 Altogether, estrogens may favorably modify diabetes risk. In contrast to tamoxifen, which functions as an estrogen modulator through competitive antagonism at its receptor, AIs markedly suppress estrogen levels in postmenopausal women by inactivating the aromatase enzyme responsible for the synthesis of estrogens from androgenic substrates 35 ; therefore, their effect on estrogen levels is expected to be more pronounced, which corroborates our results.
The distortion produced by some risk factors of the disease, years of education, and recency of breast cancer diagnosis in particular led to an underestimation (negative confounding) of the true HT-diabetes association, as evident in the weaker crude estimates compared with the adjusted ones. The majority of studies in this field, however, have not addressed such risk factors to obtain a more precise estimate of the true association, which in turn may be a major reason for the inconsistency in results.
The findings of this study should be interpreted within the scope of certain methodological shortcomings. The sample reflects breast cancer survivors in one of four health care funds in Israel, which may limit the generalizability of the findings to other settings. However, the National Health Insurance Law in Israel allows all citizens to be registered with and move among any of these funds without preliminary conditions, which reduces the potential for a selection bias. A potential bias as a result of lack of power limits the interpretability of stratified results. However, the credibility of the primary results should be unaffected because these results remained robust in a wide range of sensitivity models. Notwithstanding, comprehensive information was collected; residual confounding of uncontrolled factors predisposing to diabetes, such as lifestyle behavior, could potentially bias the results. Although these factors were available at the time of survey, to avoid potential reverse causality, they were not accounted for in the risk analyses. Finally, self-reported data, particularly work history, could be subject to recall bias. However, cancer and treatment are life-altering events, and women probably would recall their employment status reliably in relation to them. 36 With these limits in mind, we believe that the results make pivotal contributions to the limited information currently available on diabetes and have important implications on breast cancer survivorship care. Given the high prevalence of diabetes above Table 3 .
jco.org national standards, the dramatic increase in this prevalence within a relatively brief time, and the establishment of HT as a risk factor that accounts for . 45% of diabetes incidence at the breast cancer survivor population level, survivors who receive HTmust be closely monitored if the estimated reduction in diabetes burden is to be achieved. Practically, HT is amenable to intervention, yet breast cancer survivors should not be denied this treatment because the survival benefits of HT outweigh the risks. Focus should be redirected to shared modifiable risk factors, such as lifestyle. Despite current breast cancer survivorship follow-up care plans 27 that include recommendations of counseling on healthy lifestyle modification, the issue of regular screening tests for diabetes and implementation of timely preventive interventions falls between the cracks.
In conclusion, HT is a significant risk factor of diabetes among breast cancer survivors. The underlying mechanism is unclear, and additional research is warranted. Although cessation of treatment is not recommended and progression of breast cancer often is inevitable, devised strategies aimed at lifestyle modifications in patients at high risk of diabetes could at least preserve the natural history of breast cancer.
